---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-010359"
form_type: "8-K"
ticker: "OMER"
cik: "0001285819"
company_name: "OMEROS CORP"
filed_at: "2024-04-01T23:59:59+00:00"
generated_at: "2026-06-04T04:23:47.866188+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Omeros posts Q4 net loss $9.1M, secures $115.5M from OMIDRIA royalty sale

## Summary
- Q4 2023 net loss $9.1M ($0.15/sh) vs Q3 loss $37.8M; full-year net loss $117.8M ($1.88/sh) vs prior-year net income $47.4M.
- Amended OMIDRIA royalty deal with DRI: received $115.5M; DRI gets all U.S. royalties through 2031; Omeros retains ex-U.S. & post-2031 global royalties; potential $55M milestones.
- Cash and investments $171.8M at Dec 31, 2023; plus $115.5M from DRI in Feb 2024; expects ~$230M at Mar 31, 2024 after share repurchases.
- Narsoplimab BLA resubmission in TA-TMA still under FDA discussion; unable to estimate timing for submission or approval.
- OMS906 Phase 2 trials in PNH fully enrolled; positive interim data; Phase 3 targeted late 2024; OMS1029 Phase 1 multiple-ascending dose completed.

## SEC filing metadata
- accession: 0001437749-24-010359
- form_type: 8-K
- ticker: OMER
- cik: 0001285819
- company_name: OMEROS CORP
- filed_at: 2024-04-01T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1285819/000143774924010359/0001437749-24-010359-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1285819/000143774924010359/omer20231204_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-010359
- JSON: https://secwatch.observer/filing/0001437749-24-010359.json
- Plain text: https://secwatch.observer/filing/0001437749-24-010359.txt

## Key facts
- Earnings Releases
  OMEROS CORP reported the fourth quarter and year ended December 31, 2023 results: net income Net loss for the fourth quarter of 2023 was $9.1 million, or $0.15 per share, EPS net loss of $117.8 million, or $1.88 per share.
  - Period: the fourth quarter and year ended December 31, 2023
  - Net income: Net loss for the fourth quarter of 2023 was $9.1 million, or $0.15 per share
  - EPS: net loss of $117.8 million, or $1.88 per share
  - Result: reported results
  source text: Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders, today announced recent highlights and developments as well as financial results for the fourth quarter and year ended December 31, 2023, which include: ● Net loss for the fourth quarter of 2023 was $9.1 million, or $0.15 per share, compared to a net loss of $37.8 million, or $0.60 per share for the third quarter of 2023. Net loss from continuing operations was $39.3 million for the 2023 fourth quarter compared to $51.7 million for the prior quarter. ● For the year ended December 31, 2023, net loss was $117.8 million, or $1.88 per share, compared to net income of $47.4 million, or $0.76 per share, in the prior year.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1285819/000143774924010359/0001437749-24-010359-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.